SonoSite, Inc. (Nasdaq:SONO), the world leader and
specialist in hand-carried ultrasound for the point-of-care,
announced today that the company has received FDA 510(k) clearance
for its new NanoMaxx™ ultrasound system and is commencing US
customer deliveries. International deliveries began at the end of
June.
Based on SonoSite’s 4th generation Turbo technology, the six
pound NanoMaxx system is the latest addition to SonoSite’s suite of
specialized products for point-of-care visualization in medicine.
Complete with streamlined one button optimization technology, a
touch screen user interface and SonoSite’s industry-leading 5-year
warranty, the NanoMaxx system is ideal for both hospital and office
markets and designed to provide healthcare professionals with
improved patient safety practices, expanded workflow capabilities
and exam room flexibility.
Among the first to take delivery of a system, the Queensland
Ambulance Service in Australia, is integrating ultrasound into
their rapid response vehicle. “Ultrasound is an essential tool for
providing immediate diagnostics, improving patient safety and
ultimately raising the standard of patient care,” said Stephen
Rashford, MD, the department’s medical director. “With a
hand-carried system, our department will be able to assess and
diagnose patients at the scene of an accident, such as aggressively
managing chest injuries, and for higher level trauma cases,
pre-notify the hospital of a patient’s arrival to guarantee the
availability of an operating room.”
One Button Control for
Increased Efficiency
The new ultra portable and one button design of the NanoMaxx
system makes high quality ultrasound available to a much broader
range of clinicians. The system incorporates SonoSite’s advanced
proprietary imaging algorithms, including SonoMB™ and SonoAdapt™ to
deliver superior image quality in a lightweight, rugged form
factor.
With a touch screen that responds easily to the tap of a finger,
and one button optimization, clinicians can readily acquire high
resolution images to increase clinical productivity at the
point-of-care. A system boot-up time of less than 20 seconds and
long battery life further enhance workflow when using the NanoMaxx
system.
Reduce Length of Stay. Improve
Patient Safety.
Designed to help hospitals meet the new standards of patient
care, the NanoMaxx is the perfect diagnostic ultrasound for
clinical assessment and procedural guidance at the hospital bedside
and in the physician’s office. The ultimate tool for reducing
patient safety risks and healthcare delivery costs, the use of
bedside ultrasound is proven to increase the accuracy of
interventional procedures and the use of ultrasound guidance is now
recommended by two government-based agencies1 and three US medical
societies2.
At introduction, the NanoMaxx tool is available with a
complement of five transducers to support a wide range of
examinations and procedures including thoracic assessment for
pathology, vascular access, needle aspirations and injections, as
well as abdominal, cardiac, nerve, OB/Gyn, musculoskeletal, small
parts and vascular scanning. The clinical capabilities of the
NanoMaxx will help eliminate the risk and cost of transporting
patients to the imaging lab for many examinations and
procedures.
Mount it. Carry it. Or Use it
on a Stand.
The small footprint of the system, along with its space-saving
solutions, enables seamless integration with a multitude of
exam-room configurations. For convenience and flexibility, the
system can be wall mounted, placed on an exam table with kickstand
attached, or used from a highly maneuverable stand. Physicians can
easily carry the NanoMaxx tool from room-to-room, to a satellite
office, to the operating room or to a field site for immediate
use.
Drop Tested at 3
Feet
The NanoMaxx system’s highly integrated architecture and
ruggedized design, including the industry’s first elastomeric
bumper for extra durability, plus magnesium outer shell, allows it
to be used in the most demanding and austere environments. Proving
its reliability, the NanoMaxx system and its transducers
successfully passed SonoSite’s standard three foot durability drop
test.
In addition, to further reduce the risk of infection, the
NanoMaxx system’s fluid-resistant user interface makes the system
easy to clean and disinfect, helping to address the growing concern
over infection control in the medical community.
Affordable and Easily
Accessible with Web-Based Purchasing Program
Affordably priced, the NanoMaxx system and its transducers
include SonoSite’s industry-leading 5-year warranty, to provide the
lowest cost of ownership in ultrasound.
Also, SonoSite’s One-to-One Purchase Program further extends the
cost saving advantages of the NanoMaxx ultrasound tool by replacing
or complementing the traditional on-site, pre-sale demonstration
with a personal phone consultation and webcast demonstration
provided by a professional clinical sales consultant. Visit the
NanoMaxx ultrasound tool website to learn more about SonoSite’s
newest system and to experience a personal, interactive product
demo. In addition, Apple® iPhone® and iPod® mobile device users can
view a video of the NanoMaxx system on SonoSite’s new SonoAccess™
application.
About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world
leader in hand-carried ultrasound. Headquartered near Seattle, the
company is represented by ten subsidiaries and a global
distribution network in over 100 countries. SonoSite’s small,
lightweight systems are expanding the use of ultrasound across the
clinical spectrum by cost-effectively bringing high performance
ultrasound to the point of patient care. The company employs
approximately 750 people worldwide.
Forward-looking Information and the Private Litigation Reform
Act of 1995
Certain statements in this press release relating to the market
acceptance of our products, possible future sales relating to
expected orders, and our future financial position and operating
results are “forward-looking statements” for the purposes of the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are based on the
opinions and estimates of our management at the time the statements
are made and are subject to risks and uncertainties that could
cause actual results to differ materially from those expected or
implied by the forward-looking statements. These statements are not
guaranties of future performance and are subject to known and
unknown risks and uncertainties and are based on potentially
inaccurate assumptions. Factors that could affect the rate and
extent of market acceptance of our products, the receipt of
expected orders, and our financial performance include our ability
to successfully manufacture, market and sell our ultrasound
systems, our ability to accurately forecast customer demand for our
products, our ability to manufacture and ship our systems in a
timely manner to meet customer demand, variability in quarterly
results caused by the timing of large project orders from
governmental or international entities and the seasonality of
hospital purchasing patterns, timely receipts of regulatory
approvals to market and sell our products, regulatory and
reimbursement changes in various national health care markets,
constraints in government and public health spending, the ability
of our distribution partners and other sales channels such as the
physician office sales force to market and sell our products, the
impact of patent litigation, our ability to execute our acquisition
strategy, the effect of transactions and activities associated with
our issuance of senior convertible debt in July 2007 on the market
price of our common stock, and as well as other factors contained
in the Item 1A. “Risk Factors” section of our most recent Annual
Report on Form 10-K, as updated by our most recent quarterly
reports filed on Form 10-Q filed with the Securities and Exchange
Commission. We caution readers not to place undue reliance upon
these forward-looking statements that speak only as to the date of
this release. We undertake no obligation to publicly revise any
forward-looking statements to reflect new information, events or
circumstances after the date of this release or to reflect the
occurrence of unanticipated events.
iPhone and iPod are trademarks of Apple, Inc., registered in the
US and other countries.
1 Agency for Health Care Research and Quality (AHRQ) report:
Making Healthcare Safer: A Critical Analysis of Patient Safety
Practices 2001.
National Institute for Clinical Excellence (NICE) report:
Guidance on the Use of Ultrasound Locating Devices for Placing
Central Venous Catheters. 2002.
2 The American Board of Internal Medicine. "Training and
Procedural Requirements; Critical Care Medicine." Critical Care Medicine Policies. 2009. The American Board of
Internal Medicine. .
The American College of Chest Physicians. “Consensus Statement;
La Societe de Reanimation de Langue Francaise Statement on
Competence in Critical Care Ultrasonography.” 135 (2009):
1050-1060.
The American College of Emergency Physicians.“Policy Statement;
Emergency Ultrasound Guidelines.” 53 (2009): 550-70.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6065612&lang=en
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Jul 2023 to Jul 2024